Inovio Pharmaceuticals, Inc. (Nasdaq: INO) announced that its novel DNA-based monoclonal antibody technology will be deployed to develop products which ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE